For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy.
The nausea and vomiting experienced by one in four cancer patients in anticipation of chemotherapy is probably a learned response to treatment . To determine whether behavioral approaches for altering learned responses might be useful treatments for these symptoms , we compared the effects of " systematic desensitization " ( a behavioral treatment in which relaxation is learned as a response to situations in which patients have had anticipatory nausea and vomiting ) with those of counseling and of no treatment .  Sixty ambulatory cancer patients with anticipatory nausea and vomiting before their third and fourth chemotherapy treatments were r and omized equally to the three groups . Significantly more patients receiving desensitization reported no anticipatory nausea before their fifth and sixth chemotherapy treatments than patients given counseling ( P less than 0.05 ) or no treatment ( P less than 0.01 ) . Desensitized patients also reported significantly less severe anticipatory nausea ( P less than 0.01 ) and vomiting ( P less than 0.05 ) and a shorter duration of anticipatory nausea ( P less than 0.01 ) . We conclude that systematic desensitization appears to have an antiemetic effect in cancer patients who receive chemotherapy , and may be useful in the management of these problems
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .